CSIMarket Company Name, Ticker, Suppliers, else..
 
Silexion Therapeutics Corp  (NASDAQ: SLXN)
 
Price: $0.3545 $0.01 4.265%
Day's High: $0.36809998750686646 Week Perf: -0.7 %
Day's Low: $ 0.35 30 Day Perf: -15.19 %
Volume (M): 5,862,252 52 Wk High: $ 42.60
Volume (M$): $ 0 52 Wk Avg: $14.92
Open: $0.37 52 Wk Low: $0.32



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 1
 Employees 14
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on oncology. The company develops proprietary treatments for KRAS-driven cancers. Its lead product candidate, SIL204, is an RNA-interference therapeutic intended as a first-line treatment for locally advanced pancreatic cancer, combining intratumoral and systemic administration with standard chemotherapy.


   Company Address: 12 Abba Hillel Road Ramat-Gan 5250606
   Company Phone Number: 3-756-4999   Stock Exchange / Ticker: NASDAQ SLXN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Silexion’s SIL204 Emerges as a Game-Changer in Battling Pancreatic Cancer Metastasis with Promising Preclinic...

Published Thu, Sep 11 2025 11:29 AM UTC

In a significant advancement for cancer treatment, Silexion Therapeutics announced promising preclinical results regarding its novel therapeutic candidate, SIL204. The company has demonstrated that SIL204 effectively reaches major metastatic sites in pancreatic cancer, specifically the liver, peritoneum, and lung, following systemic administration. This breakthrough offers h...
Clinical Study

Silexion Therapeutics Unveils Groundbreaking Development Plan for SIL204 Ahead of 2025 NeauxCancer Conference

Published Fri, Mar 21 2025 12:48 PM UTC

: Silexion Therapeutics has announced the completion of an innovative expanded development plan for its promising therapeutic candidate, SIL204. This plan will be detailed during a presentation at the 2025 NeauxCancer Conference, a leading industry event that highlights advancements in oncology research. Recent preclinical findings from orthotopic models have shown signifi...
Clinical Study

Silexion Therapeutics Advancing Targeted Cancer Therapies to New Heights in 2024

Published Wed, Mar 19 2025 7:39 AM UTC

In the ever-evolving landscape of oncology, Silexion Therapeutics has emerged as a notable contender with significant strides in its preclinical pipeline, primarily focusing on KRAS-driven solid tumors. The latest financial results and business update for the fiscal year 2024 underscore the company s commitment to pioneering innovative therapeutic solutions that address one ...
Clinical Study

Promising Advances in SIL204 A Paradigm Shift in Pancreatic Cancer Treatment

Published Mon, Mar 10 2025 11:24 AM UTC

In recent developments that could potentially transform the landscape of pancreatic cancer therapy, Silexion Therapeutics has reported groundbreaking initial data regarding its novel therapeutic agent, SIL204. This article interprets the implications of pivotal findings related to SIL204 s systemic administration in orthotopic pancreatic cancer models, as well as its effica...
Business Update

Silexion Therapeutics Poised for Breakthrough in KRAS Cancer Treatment with Imminent Preclinical Data,

Published Mon, Mar 3 2025 5:31 PM UTC

In the ever-evolving landscape of biomedical innovation, Silexion Therapeutics (NASDAQ: SLXN) is on the verge of potentially groundbreaking advancements in the treatment of KRAS-driven cancers. Recently, PESG Research released a market update on Silexion that casts a spotlight on this pioneering biotech firm s meticulous journey and the anticipation surrounding its upcoming ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 0.00
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 5.54
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.57
Working Capital Ratio 0.94
Leverage Ratio (MRQ) 93.52
Total Debt to Equity -
Interest Coverage (TTM) 2.09
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 101.75 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 3.29 $
Book Value 0.06 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) 489,714
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 99.09 %
Return On Investment (TTM) 195.75 %
Return On Equity (TTM) 276.59 %
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.